drugset / Trial / NCT00006104
Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
Phase 2
Completed
46 enrolled
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab plus docetaxel in treating women who have recurrent or metastatic breast cancer.
Timeline
- Start
- 1998-09
- Primary completion
- 2003-07
- Completion
- 2003-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |